【摘要】目的探讨经腹腔入路一期病灶清除、自体髂骨移植、后路椎弓根固定治疗腰骶椎结核的效果。方法对2004年8月2007年6月收治12例L4～S1椎体结核,采用经腹腔入路显露腰骶椎,彻底清除病灶后用自体髂骨块椎间植骨,后路椎弓根螺钉固定;术后常规支持和抗结核治疗,术后1、3、6、9、12个月,以后每6个月一次定期随访,观察血沉变化,摄X线片、CT三维重建评估结核活动、骨块融合和畸形矫正情况。结果术中无大血管、神经、输尿管损伤,随访11～23个月,平均17个月,结核病变局部无复发,无结核性腹膜炎、性功能障碍等并发症发生。结论经腹腔前方入路暴露腰骶椎结核病灶充分、安全,病灶清除后行自体髂骨块椎间植骨、腰骶椎后路椎弓根螺钉固定可有效重建腰骶椎的稳定性。
Objective To investigate the efficacy of freeze-driedcancellous allograft in the treatment of spinal tuberculosis. Methods From January 1999 to August 2004, there were 31 cases of spinal tuberculosis who underwent surgery. The freeze-dried cancellous allograft was used as grafting material in all the cases.The cancellous allograft was packed in a titanium mesh cage or an artificial vertebrae, and then used as a strut graft anteriorly to implant into the bone defect after the redical debridement, and the instrumentation was done. Results Twenty-three cases were followed up 1.5 years to 5 years (3.7 years on average), and bonyfusion was achieved in 21 cases 6 months later. In 2 cases ceasing antituberculous therapy after 2 months of operation, the local recurrence was obvious. The loosened screw was noticed in one of these two cases, who had tuberculosis in lumbar spine. When antituberculous therapy continued, the bony fusion was observed in these two cases 12 months later. No further position change of the instrument wasnoticed in the patient carrying loosened screw, but the kyphosis of the thoracolumbar spine aggravated. Conclusion Freeze-dried cancellous allograft could be usedin the treatment of spinal tuberculosis. To achieve good results of allograft incorporation and remodeling, the rigid instrumentation should be performed, postoperative antituberculous therapy is also important.
Objective To evaluate the efficacy and safety of rifampicin plus pyrazinamide versus isoniazid for prevention of tuberculosis among persons with or without HIV-infection respectively. Methord Meta-analysis of randomized controlled trials(RCT) and quasi-randomized controlled trials(quasi RCT) that compared rifampicin plus pyrazinamide for 2-3 months with isoniazid for 6-12 months. Endpoints were development of active tuberculosis, severe adverse effects, and death. Treatment effects were summarized as risk difference (RD) with 95% confidence interval (CI). Results Three trials conducted in HIV-infected patients and 3 trials conducted in HIV-uninfected persons were identified. The rates of tuberculosis in the rifampicin plus pyrazinamide group were similar to that in the isoniazid group, whether the subjects were HIV-infected patients or not (for HIV-infected patients: pooled RD= 0%, 95%CI: -1% to 2%, P=0.89; for HIV-uninfected persons: pooled RD=0%, 95%CI: -2% to 1%, P=0.55). There was no difference in mortality between the two treatment groups (for HIV-infected patients: pooled RD=-1%, 95%CI: -4% to 2%, P=0.53; for HIV-uninfected persons: pooled RD=0%, 95%CI: -1% to 1%, P=1.00). However, both subgroup analyses showed that a higher incidence of all severe adverse events was associated with rifampicin plus pyrazinamide than isoniazid among HIV-uninfected persons (one: RD=29%, 95%CI: 13% to 46%; P=0.000 5; another: RD=7%, 95%CI: 4% to 10%; Plt;0.000 1). Conclusion Rifampicin plus pyrazinamide is equivalent to isoniazid in terms of efficacy and mortality in the treatment of latent tuberculosis infection. However, this regimen increases risk of severe adverse effects compared with isoniazid in HIV-uninfected persons.
ObjectiveTo explore distribution characteristics of drug-resistant mutations and analyze drug-resistant genotypes in Mycobacterium tuberculosis in Deyang district, Sichuan. MethodsA total of 257 patients infected with Mycobacterium tuberculosis and positive for mycobacterium tuberculosis DNA who were detected from February 2010 to March 2013 were included in our research. Drug-resistance mutations were detected and analyzed using gene chip technology combining by polymerase chain reaction (PCR) and reverse dot hybridization (RDB). ResultsIn these 257 pulmonary tuberculosis patients, drug-resistance mutations were detected in 49 with pulmonary tuberculosis. Drug-resistance mutation rate at katG 315, rpsL 43, embB 306 and rpoB 531 (S531L) was 11.67% (30/257), 7.00% (18/257), 4.28% (11/257) and 3.89% (10/257), respectively. In 234 initially treated pulmonary tuberculosis patients, the rate of isoniazid-resistant genotype, rifampicin-resistant genotype, ethambutol-resistant genotype, streptomycin-resistant genotype and multi-drug resistant genotype was 9.83%, 4.27%, 3.42%, 5.13% and 2.99%, respectively. In 23 retreated pulmonary tuberculosis patients, these rates was 52.17%, 26.09%, 13.04%, 43.48% and 13.04%, respectively. ConclusionIn Deyang district, Sichuan, drug-resistant genotypes for isoniazid, rifampicin, ethambutol and streptomycin are detected in Mycobacterium tuberculosis. Most of the drug-resistant mutations occur at katG 315, rpsL 43, embB 306 and rpoB 531. The rates of drug-resistant genotypes and multi-drug resistance in initially treated pulmonary tuberculosis patients are lower than those in retreated patients. Multi-drug resistant rate is relatively low in our research.
ObjectivesTo systematically review the disease burden and epidemiological characteristics of tuberculosis in the Chinese population, and to provide reference for health resources allocation and health policy making.MethodsDatabases such as PubMed, EMbase, CNKI, VIP and WanFang Data were searched for studies investigating disease burden of tuberculosis in Chinese population from inception to August 1st, 2017. Two researchers independently screened literature, exacted data and assessed methodological quality of included studies. Statistical analysis was performed on data of tuberculosis associated population, mortality and disease burden.ResultsA total of 40 studies were included. The results of qualitative analysis showed that, since 1990, the prevalence of tuberculosis and its disease burden in China decreased year by year. However, the disease burden per patient and the total economic burden in China showed an increasing trend, and the economical disease burden increased 1.6 times from 1993 to 2003. The disease burden of men was higher than that of women, and it was higher in the countryside than in the city. In 2004, the ratio of YLL per thousand people in rural and urban areas was 2.18, and the ratio was 1.29 in 2014. Additionally, the disease burden decreased gradually in western, central and eastern regions. In 2014, compared with 2004, YLL decreased by 1.11, while the central and eastern regions were 0.48 and 0.25, respectively. The gap between the gender, the urban and rural areas and the regions was not as significant as in previous.ConclusionsThe disease burden of tuberculosis in China is seriously high and the tuberculosis prevention and control work should take into consideration the epidemiological characteristics of tuberculosis and the trends of the disease burden. It is necessary to rationally and effectively implement health intervention programs and allocate health resources based on different health demands in different regions and age groups to reduce the morbidity and mortality, and to pay more attention to drug-resistant tuberculosis. Besides, the emphasis of prevention should be placed on reducing disease burden in the elderly and strengthening prevention in the young population.
Ferroptosis is a unique way of cell death discovered in recent years, which involves the lethal process of iron ion accumulation and lipid peroxidation, which is obviously different from the traditional cell death pathway such as apoptosis and necrosis. For a long time, tuberculosis has been a major infectious disease in the field of global public health, which brings a serious burden to the society because of its high morbidity and mortality. The emergence of drug resistance aggravates the difficulty of treating tuberculosis, and new treatment strategies and drug targets are urgently needed. Combined with the latest research progress at home and abroad, This article will discuss the molecular mechanism of ferroptosis and pulmonary tuberculosis and the relationship between signal pathways, biomarkers and related genes, in order to provide a new perspective for the diagnosis and treatment of pulmonary tuberculosis.